| ALS genetics, mechanisms, and therapeutics: where are we now? R Mejzini, LL Flynn, IL Pitout, S Fletcher, SD Wilton, PA Akkari Frontiers in neuroscience 13, 1310, 2019 | 710 | 2019 |
| Regulation of eukaryotic gene expression by the untranslated gene regions and other non-coding elements LW Barrett, S Fletcher, SD Wilton Cellular and molecular life sciences 69, 3613-3634, 2012 | 700 | 2012 |
| Functional amounts of dystrophin produced by skipping the mutated exon in the mdx dystrophic mouse QL Lu, CJ Mann, F Lou, G Bou-Gharios, GE Morris, S Xue, S Fletcher, ... Nature medicine 9 (8), 1009-1014, 2003 | 593 | 2003 |
| Antisense-induced exon skipping and synthesis of dystrophin in the mdx mouse CJ Mann, K Honeyman, AJ Cheng, T Ly, F Lloyd, S Fletcher, JE Morgan, ... Proceedings of the National Academy of Sciences 98 (1), 42-47, 2001 | 540 | 2001 |
| Physical, cognitive, and mental health impacts of COVID-19 after hospitalisation (PHOSP-COVID): a UK multicentre, prospective cohort study RA Evans, H McAuley, EM Harrison, A Shikotra, A Singapuri, M Sereno, ... The Lancet Respiratory Medicine 9 (11), 1275-1287, 2021 | 507 | 2021 |
| Antisense oligonucleotide-induced exon skipping across the human dystrophin gene transcript SD Wilton, AM Fall, PL Harding, G McClorey, C Coleman, S Fletcher Molecular Therapy 15 (7), 1288-1296, 2007 | 369 | 2007 |
| Antisense oligonucleotide-induced exon skipping restores dystrophin expression in vitro in a canine model of DMD G McClorey, HM Moulton, PL Iversen, S Fletcher, SD Wilton Gene therapy 13 (19), 1373-1381, 2006 | 361 | 2006 |
| Specific removal of the nonsense mutation from the mdx dystrophin mRNA using antisense oligonucleotides SD Wilton, F Lloyd, K Carville, S Fletcher, K Honeyman, S Agrawal, ... Neuromuscular disorders 9 (5), 330-338, 1999 | 355 | 1999 |
| Clinical characteristics with inflammation profiling of long COVID and association with 1-year recovery following hospitalisation in the UK: a prospective observational study RA Evans, OC Leavy, M Richardson, O Elneima, HJC McAuley, ... The Lancet Respiratory Medicine 10 (8), 761-775, 2022 | 313 | 2022 |
| Morpholino antisense oligonucleotide induced dystrophin exon 23 skipping in mdx mouse muscle BL Gebski, CJ Mann, S Fletcher, SD Wilton Human molecular genetics 12 (15), 1801-1811, 2003 | 281 | 2003 |
| Improved antisense oligonucleotide induced exon skipping in the mdx mouse model of muscular dystrophy CJ Mann, K Honeyman, G McClorey, S Fletcher, SD Wilton The Journal of Gene Medicine: A cross‐disciplinary journal for research on …, 2002 | 278 | 2002 |
| Dystrophin expression in the mdx mouse after localised and systemic administration of a morpholino antisense oligonucleotide S Fletcher, K Honeyman, AM Fall, PL Harding, RD Johnsen, SD Wilton The Journal of Gene Medicine: A cross‐disciplinary journal for research on …, 2006 | 270 | 2006 |
| Morpholino oligomer–mediated exon skipping averts the onset of dystrophic pathology in the mdx mouse S Fletcher, K Honeyman, AM Fall, PL Harding, RD Johnsen, JP Steinhaus, ... Molecular Therapy 15 (9), 1587-1592, 2007 | 235 | 2007 |
| Prevention of dystrophic pathology in severely affected dystrophin/utrophin-deficient mice by morpholino-oligomer-mediated exon-skipping A Goyenvalle, A Babbs, D Powell, R Kole, S Fletcher, SD Wilton, ... Molecular Therapy 18 (1), 198-205, 2010 | 172 | 2010 |
| The influence of antisense oligonucleotide length on dystrophin exon skipping PL Harding, AM Fall, K Honeyman, S Fletcher, SD Wilton Molecular Therapy 15 (1), 157-166, 2007 | 160 | 2007 |
| Induced dystrophin exon skipping in human muscle explants G Mcclorey, AM Fall, HM Moulton, PL Iversen, JE Rasko, M Ryan, ... Neuromuscular Disorders 16 (9-10), 583-590, 2006 | 154 | 2006 |
| Target selection for antisense oligonucleotide induced exon skipping in the dystrophin gene SJ Errington, CJ Mann, S Fletcher, SD Wilton The Journal of Gene Medicine: A cross‐disciplinary journal for research on …, 2003 | 147 | 2003 |
| Antisense oligonucleotides for inducing exon skipping and methods of use thereof SD Wilton, S Fletcher, G McClorey US Patent 7,807,816, 2010 | 138 | 2010 |
| Antisense oligonucleotides for inducing exon skipping and methods of use thereof SD Wilton, S Fletcher, G McClorey US Patent 8,232,384, 2012 | 130 | 2012 |
| Cell-penetrating peptide–morpholino conjugates alter pre-mRNA splicing of DMD (Duchenne muscular dystrophy) and inhibit murine coronavirus replication in vivo HM Moulton, S Fletcher, BW Neuman, G McClorey, DA Stein, S Abes, ... Biochemical Society Transactions 35 (4), 826-828, 2007 | 126 | 2007 |
Steve WiltonFoundation Chair in Molecular Therapies, Murdoch University在 ccg.murdoch.edu.au 的电子邮件经过验证
